By Fineline Cube 
Full-Life Technologies announced the successful completion of a $150 million financing round, comprising $110 million in Series D equity and $40 million in debt financing. The round was led by Vivo Capital and included participation from strategic partner SK Biopharmaceuticals Co., Ltd., alongside existing investors Chengwei Capital, HSG, Junson Capital, Yunion, Plaisance, Sky9 Capital, TSG Capital, and other prominent shareholders.
Financing Structure & Investor Consortium
| Component | Amount | Lead/Key Participants |
|---|---|---|
| Series D Equity | $110M | Vivo Capital (lead), SK Biopharmaceuticals (strategic) |
| Debt Financing | $40M | Consortium of institutional lenders |
| Total Raised | $150M | Multi-tier investor syndicate |
Clinical Pipeline Advancement
The proceeds will primarily accelerate Full-Life’s clinical-stage radiopharmaceutical pipeline, with focus on two lead candidates:
- [²²⁵Ac]Ac-FL-020: A potential best-in-class therapeutic for prostate cancer, leveraging the company’s proprietary targeting technology
- [²²⁵Ac]Ac-FL-261: A potential first-in-class drug for multiple solid tumor indications, representing novel mechanism of action in the radiopharmaceutical space
By year-end 2026, Full-Life expects to have three differentiated clinical-stage programs advancing simultaneously, all originating from its proprietary UniRDC discovery platform that enables rapid identification and optimization of radiopharmaceutical candidates.
Strategic Manufacturing Initiative
A significant portion of the funding will support the initiation of GMP-grade ²²⁵Ac (Actinium-225) isotope production at the company’s advanced manufacturing facility in Belgium. This vertical integration strategy addresses critical industry constraints:
- Supply Chain Security: Independent control over ²²⁵Ac production eliminates reliance on limited global suppliers
- Quality Assurance: In-house GMP production ensures consistent isotope quality for clinical and commercial supply
- Scalability: Dedicated production capacity enables rapid scale-up to meet anticipated clinical trial and commercial demand
- Competitive Moat: Proprietary isotope production capability represents a significant strategic advantage in the capital-intensive radiopharmaceutical sector
Market Context & Industry Dynamics
- Radiopharmaceutical Renaissance: The targeted alpha therapy market is projected to reach $8.5 billion by 2030, growing at 18% CAGR, driven by superior efficacy and safety profiles compared to traditional radiotherapies
- Isotope Scarcity Challenge: Global ²²⁵Ac supply currently meets less than 30% of projected clinical demand, creating significant barriers to entry for new players
- Asian Innovation Hub: Full-Life represents the vanguard of Chinese biotech companies expanding globally in specialized therapeutic areas, with European manufacturing ensuring regulatory compliance across major markets
- Strategic Partnership Value: SK Biopharmaceuticals’ participation signals strong validation of Full-Life’s technology platform and provides potential commercialization pathways in Asia-Pacific markets
Forward-Looking Statements
This brief contains forward-looking statements regarding clinical development timelines, manufacturing capabilities, and market opportunities. Actual results may differ due to risks including regulatory approvals, clinical trial outcomes, manufacturing scale-up challenges, and competitive dynamics in the radiopharmaceutical sector.-Fineline Info & Tech